Core Viewpoint - The FDA has announced a significant policy change that will gradually eliminate the mandatory requirement for animal testing in the development of certain new drugs, particularly monoclonal antibody therapies, which has raised concerns in the pharmaceutical industry and led to stock price declines for companies reliant on traditional animal testing methods [1] Group 1: Policy Changes - The FDA's new policy aims to encourage the use of alternative methods, such as AI algorithms and organoid technology, to reduce or replace animal testing in drug development [1] - This policy shift is seen as a more concrete approach compared to previous efforts, providing a clear example for the industry to follow [1] Group 2: Industry Impact - The cost and time associated with animal testing have been significant issues, with the price of experimental monkeys increasing dramatically from approximately 6,500 yuan per monkey in 2014 to 150,000 yuan per monkey in 2022 [1] - Leading domestic companies have previously invested in experimental animals, and the new FDA policy may disrupt their business models [1] Group 3: Future Considerations - Industry experts indicate that while the FDA's policy provides a foundation for reducing animal testing, more clinical data is needed to demonstrate that organoids can effectively predict toxicity and potentially surpass the efficacy of animal testing [1]